Skip to content

The ESTxENDS Trial- Substudy on the Effect on Toxins From Using Electronic Nicotine Delivery Systems (ENDS/Vaporizer/E-cig)

Substudy of Efficacy, Safety and Toxicology of Electronic Nicotine Delivery Systems as an Aid for Smoking Cessation (ESTxENDS Trial)- the Toxins Substudy of ESTxENDS

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03612544
Acronym
ESTxENDS
Enrollment
1246
Registered
2018-08-02
Start date
2018-07-16
Completion date
2023-08-31
Last updated
2023-11-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Smoking Cessation, Toxicity

Brief summary

--\> This is a substudy of the main ESTxENDS trial (NCT03589989). Toxins outcomes should be considered secondary outcomes of the main smoking cessation outcome formulated in NCT03589989. Cigarette smoking is the leading cause of preventable death in Switzerland. Recently, electronic nicotine delivery systems (ENDS; also called vaporizer or electronic cigarette) have become popular with smokers who want to stop smoking or reduce their exposure to inhaled chemicals since ENDS use appears to be safer than tobacco smoking. Conventional cigarettes release toxic chemicals in tobacco smoke through thermochemical degradation and pyrolysis processes by combusting tobacco, but in ENDS toxicants can be released by heating up nicotine-containing e-liquids to produce vapor. The e-liquid in ENDS is mostly made of propylene glycol (PG) and vegetal glycerin (VG) in addition to nicotine, flavorings and sometimes alcohol as a conservation agent. The heating process of the e-liquid in ENDS, has been shown to release carcinogens such as some carbonyl and volatile organic compounds (i.e., formaldehyde, acetaldehyde and acrolein). Some devices might also release heavy metals such as cadmium, lead and mercury. The source of such metals may be the metal of the device or the e-liquids. Although unexpected from the composition of the e-liquids, some studies have also detected tobacco-specific nitrosamines (TNSAs) (N'-nitrosonornicotine (NNN) and 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone (NNK)) and polycyclic aromatic hydrocarbons (PAHs) (1- and 2-Naphtol and 1-hydroxypyrene (1-OHP)). This study will therefore test the efficacy of ENDS for cigarette smoking cessation, the safety of ENDS on adverse events and the effect of ENDS on health-related outcomes and exposure to inhaled chemicals. For the main ESTxENDS trial (NCT03589989), cigarette smokers motivated to quit smoking cigarettes will be included. Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants in the control group will receive smoking cessation counseling only. All participants will be followed over a 24-month period. Chemicals such as VOCs, PAHs, TSNAs, heavy metals, nicotine and nicotine degradation products will first be quantified in the aerosol produced by ENDS in laboratory conditions. These chemicals and their metabolites will then be measured at baseline and at 6-, 12- and 24- months' follow-up in urine samples from study participants.

Interventions

Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.

OTHERSmoking cessation counseling

Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.

Sponsors

University of Lausanne
CollaboratorOTHER
University of Geneva, Switzerland
CollaboratorOTHER
University of Zurich
CollaboratorOTHER
State Hospital, St. Gallen
CollaboratorOTHER_GOV
Swiss National Science Foundation
CollaboratorOTHER
Krebsforschung Schweiz, Bern, Switzerland
CollaboratorOTHER
Federal Office of Public Health, Switzerland
CollaboratorOTHER_GOV
University of Bern
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Masking description

Statisticians and laboratory personnel will be blinded to group allocation.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Informed Consent as documented by signature * Persons aged 18 or older * Currently smoking 5 or more cigarettes a day for at least 12 months * Willing to try to quit smoking within the next 3 months, * Persons providing a valid phone number, a valid email address and/or a valid postal address.

Exclusion criteria

* Known hypersensitivity or allergy to contents of the e-liquid * Participation in another study with investigational drug within the 30 days preceding the baseline visit and during the present study where interactions are to be expected * Women who are pregnant or breast feeding * Intention to become pregnant during the course of the scheduled study intervention, i.e. within the first 6-months of the study * Persons having used ENDS or tobacco heating systems regularly in the 3 months preceding the baseline visit * Persons having used nicotine replacement therapy (NRT) or other medications with demonstrated efficacy as an aid for smoking cessation such as varenicline or bupropion within the 3 months preceding the baseline visit * Persons who cannot attend the 6- month follow-up visit for any reason * Cannot understand instructions delivered in person or by phone, or otherwise unable to participate in study procedures

Design outcomes

Primary

MeasureTime frameDescription
Concentrations of urinary nicotine metabolites_324 months post quit dateMeasurement of nicotine metabolites in urine
Concentrations of urinary PAHs (Polycyclic aromatic hydrocarbons)_212 months post quit dateMeasurement of PAHs (Polycyclic aromatic hydrocarbons) in urine
Concentrations of urinary PAHs (Polycyclic aromatic hydrocarbons)_324 months post quit dateMeasurement of PAHs (Polycyclic aromatic hydrocarbons) in urine
Concentrations of urinary heavy metals_16 months post quit dateMeasurement of heavy metals in urine
Concentrations of urinary heavy metals_212 months post quit dateMeasurement of heavy metals in urine
Concentrations of urinary heavy metals_324 months post quit dateMeasurement of heavy metals in urine
Concentrations of urinary nicotine metabolites_16 months post quit dateMeasurement of nicotine metabolites in urine
Concentrations of urinary nicotine metabolites_212 months post quit dateMeasurement of nicotine metabolites in urine
Concentrations of urinary NNAL (4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol)_16 months post quit dateMeasurement of NNAL (4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol) in urine
Concentrations of urinary NNAL (4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol)_212 months post quit dateMeasurement of NNAL (4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol) in urine
Concentrations of urinary NNAL (4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol)_324 months post quit dateMeasurement of NNAL (4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol) in urine
Concentrations of urinary NNN (N-nitrosonornicotine)_16 months post quit dateMeasurement of NNN (N-nitrosonornicotine) in urine
Concentrations of urinary NNN (N-nitrosonornicotine)_212 months post quit dateMeasurement of NNN (N-nitrosonornicotine) in urine
Concentrations of urinary NNN (N-nitrosonornicotine)_324 months post quit dateMeasurement of NNN (N-nitrosonornicotine) in urine
Concentrations of urinary NNK (nicotine-derived nitrosamine ketone)_16 months post quit dateMeasurement of NNK (nicotine-derived nitrosamine ketone) in urine
Concentrations of urinary NNK (nicotine-derived nitrosamine ketone)_212 months post quit dateMeasurement of NNK (nicotine-derived nitrosamine ketone) in urine
Concentrations of urinary NNK (nicotine-derived nitrosamine ketone)_324 months post quit dateMeasurement of NNK (nicotine-derived nitrosamine ketone) in urine
Concentrations of urinary metabolites of VOCs (volatile organic compounds)_16 months post quit dateMeasurements of metabolites of VOCs in urine
Concentrations of urinary metabolites of VOCs (volatile organic compounds)_212 months post quit dateMeasurements of metabolites of VOCs in urine
Concentrations of urinary metabolites of VOCs (volatile organic compounds)_324 months post quit dateMeasurements of metabolites of VOCs in urine
Concentrations of urinary PAHs (Polycyclic aromatic hydrocarbons)_16 months post quit dateMeasurement of PAHs (Polycyclic aromatic hydrocarbons) in urine

Secondary

MeasureTime frameDescription
Change in concentrations of urinary NNN (N-nitrosonornicotine)Change from baseline to 6,12, 24 months post quit dateChange of NNN (N-nitrosonornicotine) concentrations in urine from baseline to 6, 12, and 24 months post quit date.
Change in concentrations of urinary NNK (nicotine-derived nitrosamine ketone)Change from baseline to 6,12, 24 months post quit dateChange of NNK (nicotine-derived nitrosamine ketone) concentrations in urine from baseline to 6, 12, and 24 months post quit date.
Change in concentrations of urinary VOCs (volatile organic compounds)Change from baseline to 6,12, 24 months post quit dateChange of VOCs (volatile organic compounds) concentrations in urine from baseline to 6, 12, and 24 months post quit date.
Change in concentrations of urinary PAHs (Polycyclic aromatic hydrocarbons)Change from baseline to 6,12, 24 months post quit dateChange of PAHs (Polycyclic aromatic hydrocarbons) concentrations in urine from baseline to 6, 12, and 24 months post quit date.
Change in concentrations of urinary heavy metalsChange from baseline to 6,12, 24 months post quit dateChange of heavy metals concentrations in urine from baseline to 6, 12, and 24 months post quit date.
Change in concentrations of urinary nicotine metabolitesChange from baseline to 6,12, 24 months post quit dateChange of nicotine metabolites concentrations in urine from baseline to 6, 12, and 24 months post quit date.
Change in concentrations of urinary NNAL (4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol)Change from baseline to 6,12, 24 months post quit dateChange of NNAL (4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol) concentrations in urine from baseline to 6, 12, and 24 months post quit date.

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026